BYRAYIC
DEAD

Serial Number

90006127

Owner

ALLERGAN SALES, LLC

Attorney

Cheryl A. Withycombe

Filing Date

Jun 17, 2020

Add to watchlist:

No watchlists yet
View on USPTO

BYRAYIC Trademark

Serial Number: 90006127

BYRAYIC is a trademark filed by ALLERGAN SALES, LLC on June 17, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

June 17, 2020

Registration Date

Not Registered

Published for Opposition

October 20, 2020

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 18, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 18, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 7, 2021 EXRA
SOU EXTENSION 2 GRANTED
Dec 3, 2021 EX2G
SOU EXTENSION 2 FILED
Dec 3, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 3, 2021 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 2, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 2, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 2, 2021 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 10, 2021 EXRA
SOU EXTENSION 1 GRANTED
Jun 8, 2021 EX1G
SOU EXTENSION 1 FILED
Jun 8, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 8, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 15, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 20, 2020 NPUB
PUBLISHED FOR OPPOSITION
Oct 20, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 30, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 17, 2020 CNSA
ASSIGNED TO EXAMINER
Sep 17, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 15, 2020 NWOS
NEW APPLICATION ENTERED
Jun 20, 2020 NWAP